Top Medical News
Parenteral n–3 PUFA supplementation aids in recovery of CD patients after bowel resection
Stephen Padilla, Yesterday
Parenteral supplementation with n‒3 polyunsaturated fatty acids (PUFAs) helps in the recovery of patients with Crohn’s disease (CD) following bowel resection, reports a study. This intervention is also safe, as shown by the fewer complications and reduced inflammatory cytokines.
Lower VTE risk seen in atopic dermatitis vs other inflammatory diseases
Stephen Padilla, 2 days ago
Atopic dermatitis (AD) does not seem to induce an increase in the risk of venous thromboembolism (VTE) when considering underlying risk factors, suggests a study. Moreover, patients with AD show a lower VTE risk than those with rheumatoid arthritis (RA), Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA), or ankylosing spondylitis (AS).
Paediatric-onset immune-mediated inflammatory diseases raise mortality risk
2 days ago
People with paediatric-onset immune-mediated inflammatory diseases (pIMID) have a roughly fourfold increased risk of death in adulthood, as suggested in a study.
Managing diabetes in primary care
4 days ago
For individuals with diabetes mellitus (DM), optimal glycaemic control may protect against the risk of developing colonic adenoma and colorectal cancer (CRC), as reported in a population-based cohort study.
IBD a risk factor for acute coronary syndrome?
15 Apr 2024
Individuals with inflammatory bowel disease (IBD) appear to be at increased risk of acute coronary syndrome (ACS) compared with those from the general population, according to a Swedish nationwide cohort study.
Low CRC screening uptake in Singapore: Men, women face different barriers
Jairia Dela Cruz, 12 Apr 2024
Singapore sees low colorectal cancer (CRC) screening rates, and the factors that influence screening compliance seem to differ between men and women, as shown in a study.
Open-access upper endoscopy fast-tracks diagnosis for nonalarming symptoms in SG
Jairia Dela Cruz, 08 Apr 2024
Open-access esophagogastroduodenoscopy (OAE) facilitates a safe and timely evaluation of patients with nonalarming digestive issues in Singapore, according to a study.
Special Reports
Long COVID: What we have learned so far
Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Oral anticoagulant therapy for acute VTE in obese patients
Adjunct Assistant Prof. Pankaj Kumar Handa, 03 Apr 2023
Although direct-acting oral anticoagulants (DOACs) are widely recommended for first-line treatment of venous thromboembolism (VTE), their use in obese patients remains controversial due to the limited representation of such patients in clinical trials. As the prevalence of obesity continues its upward trend, clinicians increasingly have to make treatment decisions for obese patients. MIMS Doctor interviewed Adjunct Assistant Professor Pankaj Kumar Handa, Senior Consultant at Tan Tock Seng Hospital, Singapore, to gain his perspectives on oral anticoagulation in obese patients.
Apixaban may be the DOAC of choice for AF patients at risk for GI bleeding
Dr. Teo Wee Siong, 21 Jan 2023
While current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with non-valvular atrial fibrillation (NVAF), there is a lack of head-to-head trial data to guide the choice of DOAC. Esteemed expert Dr Teo Wee Siong, Consultant Cardiologist & Cardiac Electrophysiologist from Mount Elizabeth Medical Centre, Singapore, reviewed the latest data on the comparative effectiveness and safety of DOACs in AF, provided valuable insights on considerations for the selection of DOACs, and shared his clinical experience with apixaban (Eliquis, Pfizer).

Optimizing anticoagulation therapy for atrial fibrillation with prior gastrointestinal bleeding
Dr. Pipin Kojodjojo, 24 Jul 2022
Long-term anticoagulation therapy is often recommended for patients with atrial fibrillation (AF) to reduce their risk of stroke, but gastrointestinal bleeding (GIB) is a common complication that presents a significant challenge. Patients with a history of GIB have heightened risks of recurrent bleeding events, hence interruption or discontinuation of anticoagulants is often warranted. When and how to restart anticoagulant therapy following an episode of GIB has been debated. MIMS Doctor interviewed Dr Pipin Kojodjojo, Cardiologist and Cardiac Electrophysiologist at Asian Heart & Vascular Centre, Singapore, to gather his perspectives on how to manage anticoagulant therapy after a GIB episode.
Challenging the status quo: The need for a new gastric acid suppressor
03 Jun 2020
For decades, the treatment of acid-related disorders have been limited to conventional acid suppressants. However, as Dr Daphne Ang (Changi General Hospital, Singapore) explains, clinicians can now maximise acid suppression through newer acid suppressants through potassium competitive inhibition.
Role of Lactobacillus reuteri in managing functional gastrointestinal disorders in infants
Prof. Hania Szajewska, 05 Dec 2019
The three most common functional gastrointestinal (GI) disorders are regurgitation, infantile colic, and constipation. At a recent symposium, Professor Hania Szajewska from the Department of Paediatrics at the Medical University of Warsaw, Poland, discussed the role of probiotics, specifically Lactobacillus reuteri DSM 17938 (Lactobacillus reuteri Protectis) in managing these disorders.
Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma
Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).  

Conference Reports
Add-on radioligand therapy improves PFS in SSTR+ G2/G3 GEP-NETs
Elaine Soliven, 05 Mar 2024

Adding lutetium-177 (177Lu)–Dotatate radioligand therapy (RLT) to long-acting octreotide as first-line therapy significantly improves progression-free survival (PFS) in patients with newly diagnosed somatostatin receptor-positive (SSTR+), grade 2 and 3 (G2 and G3), well-differentiated gastroenteropancreatic neuroendocrine tumours (GEP-NETs) compared with high-dose long-acting octreotide alone, according to the NETTER-2 trial presented at ASCO GI 2024.

Pembrolizumab delivers long-term survival benefits in advanced esophageal cancer
Stephen Padilla, 24 Feb 2024
First-line pembrolizumab (pembro) plus chemotherapy (chemo) in patients with untreated advanced esophageal cancer demonstrates robust efficacy after 5 years, with no new safety concerns, when compared with placebo plus chemo, according to a study presented at ASCO GI 2024.
Does hand grip strength correlate with clinical disease activity in CD?
Audrey Abella, 23 Feb 2024
Hand grip may be associated with clinical disease activity in patients with Crohn’s disease (CD), but hand grip measurements alone may not be the best predictor of disease activity or related disability, suggests a study presented at Crohn’s and Colitis Congress 2024.
Thoracoscopic esophagectomy better than open surgery in esophageal cancer
Stephen Padilla, 23 Feb 2024
Thoracoscopic esophagectomy (TE) has demonstrated its noninferiority to open transthoracic esophagectomy (OE) for patients with thoracic esophageal cancer in a study presented at ASCO GI 2024.
Infliximab, vedolizumab similarly effective as 1L Tx for paediatric IBD
Audrey Abella, 22 Feb 2024
In a study presented at Crohn’s and Colitis Congress 2024, infliximab and vedolizumab were found to have similar effectiveness in achiev­ing steroid-free clinical remission (SFCR) and biochemical remission (BR) at 12 months when used as first-line treatment for biologic-naïve paediatric patients with un­complicated mild-to-moderately active inflammatory bowel disease (IBD).
Adalimumab response prevents serious infections in CD
Stephen Padilla, 18 Feb 2024
The risk of developing serious infections is much lower among patients with Crohn’s disease (CD) who showed response to adalimumab therapy than nonresponders, after accounting for disease severity, according to the results of a study presented at CCC 2024.
Does multiple biosimilar switching induce flare in IBD patients?
Stephen Padilla, 17 Feb 2024
Multiple biosimilar infliximab (IFX) switching among patients with inflammatory bowel disease (IBD) does not seem to give rise to disease flares at 12 months compared to those who continued using IFX originator or those on single IFX biosimilar switch, a study has shown.